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Inhibition of iNOS as a novel effective targeted
therapy against triple-negative breast cancer
Sergio Granados-Principal1, Yi Liu1, Maria L Guevara2, Elvin Blanco3, Dong Soon Choi1, Wei Qian1, Tejal Patel1,
Angel A Rodriguez1, Joseph Cusimano4, Heidi L Weiss5, Hong Zhao6, Melissa D Landis1, Bhuvanesh Dave1,
Steven S Gross7 and Jenny C Chang1,6*
Abstract
Introduction: Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer with no effective targeted
therapy. Inducible nitric oxide synthase (iNOS) is associated with poor survival in patients with breast cancer by
increasing tumor aggressiveness. This work aimed to investigate the potential of iNOS inhibitors as a targeted
therapy for TNBC. We hypothesized that inhibition of endogenous iNOS would decrease TNBC aggressiveness by
reducing tumor initiation and metastasis through modulation of epithelial-mesenchymal transition (EMT)-inducing
factors.
Methods: iNOS protein levels were determined in 83 human TNBC tissues and correlated with clinical outcome.
Proliferation, mammosphere-forming efficiency, migration, and EMT transcription factors were assessed in vitro after
iNOS inhibition. Endogenous iNOS targeting was evaluated as a potential therapy in TNBC mouse models.
Results: High endogenous iNOS expression was associated with worse prognosis in patients with TNBC by gene
expression as well as immunohistochemical analysis. Selective iNOS (1400 W) and pan-NOS (L-NMMA and L-NAME)
inhibitors diminished cell proliferation, cancer stem cell self-renewal, and cell migration in vitro, together with
inhibition of EMT transcription factors (Snail, Slug, Twist1, and Zeb1). Impairment of hypoxia-inducible factor
1α, endoplasmic reticulum stress (IRE1α/XBP1), and the crosstalk between activating transcription factor 3/activating
transcription factor 4 and transforming growth factor β was observed. iNOS inhibition significantly reduced tumor
growth, the number of lung metastases, tumor initiation, and self-renewal.
Conclusions: Considering the effectiveness of L-NMMA in decreasing tumor growth and enhancing survival rate in
TNBC, we propose a targeted therapeutic clinical trial by re-purposing the pan-NOS inhibitor L-NMMA, which has been
extensively investigated for cardiogenic shock as an anti-cancer therapeutic.
Introduction
Triple-negative breast cancer (TNBC) is an aggressive
and lethal form of cancer that lacks estrogen receptor
alpha (ERα), progesterone, and human epidermal growth
factor receptors with no approved targeted therapeutic
options. Despite numerous advances, treatment resistance
and metastasis are the main causes of death in patients
with TNBC. Resistance to conventional treatment and
onset of metastases may arise from a subpopulation of
cancer stem cells (CSCs) with self-renewal and tumor-
initiating capacities [1,2]. Thus, combinatorial treatments
with conventional chemotherapy and anti-CSC therapies
would be necessary to reduce tumor burden, recurrence,
and metastasis to distant organs [3,4].
Nitric oxide (NO) is a bioactive molecule that exhibits
pleotropic effects within cancer cells and tumors, with
concentration-dependent pro- and anti-tumor effects.
NO is produced by three different nitric oxide synthase
(NOS) isoforms: neuronal (nNOS/NOS1), inducible (iNOS/
NOS2), and endothelial (eNOS/NOS3) [5]. Increased iNOS
expression has been found in breast cancer [6-9] and other
different cancers such as lung [10], colon [11], melanoma
[12], and glioblastoma [13]. Previous reports have dem-
onstrated a correlation between high iNOS expression,
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aggressiveness, and poor prognosis in patients with breast
cancer [6-9]. Increased iNOS expression has recently been
postulated as a prognostic factor for reduced survival in
patients with basal-like ERα-negative breast cancer through
the induction of interleukin-8 (IL-8), CD44, c-Myc [7] and
partially due to the activation of the transcription factor
Ets-1 [14]. Here, we hypothesize that enhanced endogenous
iNOS expression drives poor patient survival by promoting
tumor relapse and metastases through modulation of
CSC self-renewal properties and tumor cell migration. We
further hypothesize that, in combination with conven-
tional chemotherapy, the inhibition of endogenous iNOS
would reduce the aggressiveness of residual TNBC cells
and mesenchymal features and the number of metastases
to distant organs, thus improving survival of patients with
TNBC. We studied the inhibition of iNOS with different
small-molecule inhibitors: the selective iNOS inhibitor
1400 W and two pan-NOS inhibitors: L-NMMA and
L-NAME. L-NMMA has been extensively studied in
hundreds of patients for cardiogenic shock [15] and, if
efficacious, would enable immediate translation into
clinical trials without the need of extensive preclinical
testing.
Methods
Reagents
N-[[3-(aminomethyl)phenyl]methyl]-ethanimidamide
(1400 W) and N5-[imino(nitroamino)methyl]-L-ornithine
methyl ester (L-NAME) were purchased from Cay-
man Chemical (Ann Arbor, MI, USA). Tilarginine (NG-
Monomethyl-L-arginine) (L-NMMA) was from Santa
Cruz Biotechnology (Dallas, TX, USA) and kindly supplied
by (Arginox Pharmaceuticals, Redwood City, CA, USA).
Tunicamycin and recombinant human TGF-β1 were
obtained from Abcam (Cambridge, UK) and Pepro-
Tech (Rocky Hill, NJ, USA), respectively. iNOS (N-20),
eNOS (C-20), nNOS (R-20), Twist1 (L-21), Twist1 (2C1a),
ATF3 (C-19), and CREB-2 (C-20) antibodies were from
Santa Cruz Biotechnology. Antibodies Snail (C15D3), Slug
(C19G7), TCF8/Zeb1 (D80D3), PERK (C33E10), TGFβ,
phospho-Smad2/3 (D6G10), Smad2/3, IRE1α (14C10),
phospho-PERK (16 F8), PERK (C33E10), phospho-eIF2α
(119A11), eIF2α, β-Actin, anti-rabbit, and anti-mouse
IgG were obtained from Cell Signaling Technology
(Danvers, MA, USA). Hypoxia-inducible factor 1α (HIF1α)
(EP1215Y) was from Abcam.
Oncomine gene expression data analysis
Relative levels of NOS2 mRNA expression in human
TNBC were investigated by Oncomine Cancer Micro-
array database analysis [16] of The Cancer Genome
Atlas (TCGA) database (n = 593). Patient survival ana-
lysis of two different gene expression data sets was
obtained [17,18].
Cell culture
Mesenchymal-like TNBC cell lines MDA-MB-231 and
SUM159 were purchased from American Type Culture
Collection (Manassas, VA, USA) and Asterand Bioscience
(Detroit, MI, USA), respectively. These cell lines were
chosen on the basis of their high expression of epithelial-
mesenchymal transition (EMT) markers, metastatic prop-
erties, percentage of CD44+/CD24− cells, iNOS protein
levels, similar protein levels of iNOS downstream targets,
and similar production of total NO (data not shown).
Cells were grown in Dulbecco’s modified Eagle’s medium
(DMEM) (Gibco, Life Technologies, Grand Island, NY
14072 USA) supplemented with 10% fetal bovine serum
and 1% antibiotic-antimycotic. Unless otherwise specified,
cells were treated daily with 1400 W (0.1, 1, 10, 100 μM;
1, 2, 4 mM), L-NMMA (0.1, 1, 10, 100 μM; 1, 2, 4 mM),
or L-NAME (0.1, 1, 10, 100 μM; 1, 2, 5 mM) for 96 hours.
For mammosphere (MS) formation (MSFE), cells were
cultured for 96 hours under treatment in 0.5% methyl-
cellulose and MammoCult basal medium (StemCell
Technologies, Vancouver, BC, Canada) supplemented
with 10% proliferation supplements, 4 μg/mL heparin, and
0.48 μg/mL hydrocortisone. Primary MSs were scanned
and counted with GelCount (Oxford Optronix, Abingdon,
UK). Secondary MSs were grown in the absence of
treatment. For the mouse model of lung metastasis,
MDA-MB-231 cells were transfected with a luciferase/
GFP-based dual-reporter plasmid and stable clones (MDA-
MB-231 L/G) selected with blasticidin (InvivoGen, San
Diego, CA, USA).
Cell proliferation assay
Proliferation of SUM159 and MDA-MB-231 was
determined by adding premixed WST-1 reagent (Clontech,
Mountain View, CA, USA). For transient knockdown in
SUM159 and MDA-MB-231 cells (500 cells per well), pro-
liferation was determined after 72 hours of transfection.
Wound healing assay
Confluent cells were treated in starvation conditions (1%
serum) for 72 hours. Medium was changed by regular
growth medium in the presence of inhibitors for 24 hours
more. For transient knockdown, cells were transfected for
72 hours in growth media. A ‘wound’ was then created in
the cell monolayer with a 100-μL pipette tip. Images were
taken at 0 and 14 hours. Data were replicated in three
independent experiments.
RNA interference experiments
SUM159 and MDA-MB-231 cells were transiently
transfected with Scrambled siRNA, siRNA1, or siRNA2
(100 nM) (Silencer Select; Ambion, Life Technologies, Grand
Island, NY 14072 USA) for 96 hours using Lipofectamine
RNAiMAX (Invitrogen, Life Technologies, Grand Island,
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NY 14072 USA) in accordance with the instructions of
the manufacturer. GIPZ lentiviral NOS2 (shRNA1 -
V3LHS_360691) and empty vector shRNAs were
purchased from Thermo Fisher Scientific. MDA-MB-231
cells were transduced with lentiviral particles and selected
with puromycin. Cells were then harvested and plated for
immunocytochemistry of iNOS.
Nitric oxide production
Cells were treated with L-NMMA or 1400 W for 24 hours
in phenol red- and serum-free DMEM. Aliquots of cell
culture supernatant were taken at 0, 0.5, 2, 6, and 24 hours
for total NO production with the nitrate/nitrite fluoromet-
ric assay kit (Cayman Chemical) in accordance with the
instructions of the manufacturer.
Western blot
Whole cell lysates were made in 1X lysis buffer (Cell
Signaling Technology) and 1X protease/phosphatase in-
hibitor cocktail (Thermo Scientific). Samples (30 μg pro-
tein) were boiled in sample buffer (Thermo Scientific)
containing β-mercaptoethanol (Sigma-Aldrich, St. Louis,
MO, USA) and subjected to SDS-PAGE electrophoresis
in 4% to 20% polyacrylamide gels (Bio-Rad, Hercules,
CA, USA). Proteins were transferred onto nitrocellulose
membranes (Bio-Rad). Membranes were incubated over-
night at 4°C with primary antibodies (1:1,000) and the
appropriate secondary antibodies for 1 hour (1:2,000).
Protein bands were developed in autoradiography films
(Denville Scientific Inc., South Plainfield, NJ, USA).
RT-PCR analysis of spliced XBP1
cDNA was synthetized from total RNA and subsequently
amplified by polymerase chain reaction (PCR). The primers
were XBP1 (5′-GGGTCCAAGTTGTCCAGAATGC-3′
and 5′-TTACGAGAGAAAACTCATGGC-3′) and β-Actin
(5′-CTGGAACGGTGAAGGTGACA-3′ and 5′-AAG
GGACTTCCTGTAACAATGCA-3′). PCR conditions
were 1 cycle at 95°C for 5 minutes, 25 cycles of 30 seconds
at 95°C, 1 minute at 50°C, and 1 minute at 68°C, followed
by 1 cycle at 68°C for 5 minutes. cDNA amplicons were
resolved in 2% agarose.
Immunohistochemistry
After antigen retrieval (Tris-Cl, pH 9.0), paraffin-embedded
sections of human patient samples and xenograft tumors
were incubated for 1 hour at room temperature with iNOS
(1:50) (Novus Biologicals, Littleton, CO, USA), Ki67 (1:100)
(Abcam), and cleaved caspase-3 (1:50) (Cell Signaling
Technology) antibodies. The iNOS score method was
as follows: intensity (0 to 3): negative, weak, moderate,
strong; distribution (0 to 4): <10%, 10% to 30%, >30%
to 50%, >50% to 80%, >80%. Total score can be divided
into four groups: negative (0 or 1), weak (2 or 3), moderate
(4 or 5), and strong (6 or 7) as previously reported [7].
MDA-MB-231 cells transfected either with NOS2-directed
shRNA (shRNA1) or empty vector were used as negative
and positive control of iNOS staining, respectively.
Animal studies
Either MDA-MB-231 or SUM159 cells (3 × 106) were
injected in the right mammary fat pad of female severe
combined immunodeficiency (SCID) Beige mice. Once
the tumors reached 150 to 200 mm3, the mice were ran-
domly assigned as follows (n = 10 per group): (1) vehicle
(saline, intraperitoneal, or i.p.), (2) L-NMMA (either
80 mg/kg or 200 mg/kg, i.p., daily), (3) docetaxel (20 mg/kg),
and (4) combo (L-NMMA and docetaxel). For the lung
metastases-preventing study, MDA-MB-231 L/G cells were
implanted as described above. The mice were randomly
assigned, and treatments started 48 hours after cell injection
(n = 5 per group): (1) vehicle (saline, i.p.) and (2) L-NAME
(80 mg/kg, i.p., daily for 35 days). Lungs were removed and
incubated in cold complete DMEM containing 50 μM lucif-
erin for 10 minutes. Luminescent cancer cells were detected
with an IVIS-200 in vivo imaging system (PerkinElmer,
Waltham, MA, USA). The clinically relevant dose regi-
men consisted on two cycles of docetaxel (20 mg/kg, i.p.,
on day 0), L-NMMA (400 mg/kg on day 1, and 200 mg/kg
for 4 additional days by oral gavage), and amlodipine on
day 0 (10 mg/kg, i.p., daily, for 6 days). Docetaxel alone as
well as saline (i.p.) + sterile water (oral gavage) were used
as controls.
MS formation and limiting dilution assay (LDA) were
assayed as previously described [4]. All animal proce-
dures and experimental protocols were approved by the
Houston Methodist Research Institute Animal Care and
Use Review Office that ensured adherence to the National
Institutes of Health Guide for the Care and Use of Labora-
tory Animals.
Metabolite profiling by liquid chromatography-tandem
mass spectrometry
Xenograft tissue as well as plasma samples were prepared
as previously described [19]. L-NMMA (200 mg/kg) was
orally administered by gavage to female SCID Beige mice
(n = 5). Blood was drawn before (baseline, 0 hours) and
after (0.5, 2, 12, and 24 hours) L-NMMA administration.
Ratiometric quantification of methylarginine (L-NMMA)
and citrulline was determined as ion abundance levels in
plasma and tumor tissue [19].
Blood pressure
Blood pressure (BP) was measured in 15 female SCID
Beige mice for 3 days (basal BP) and subsequently treated
with one cycle of the clinically relevant dose regimen
(n = 5 per group). The average daily BP was determined
by averaging the last 10 of 20 BP measurements for the
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last three consecutive days of the cycle treatment using
a computerized tail cuff monitor (BP-2000 Series II;
Visitech Systems, Napa Place, Apex, NC, USA).
Statistical analysis
All data were analyzed by using GraphPad Prism
(GraphPad Software, La Jolla, CA, USA). Data are
presented as mean ± standard error of the mean. Statis-
tical significance between two groups was analyzed by
two-tailed Student’s t test. Experiments with more than
three groups were analyzed with one-way analysis of
variance (ANOVA) and Bonferroni’s post hoc test.
Statistical analysis of tumor volume was assessed by two-
way ANOVA and Bonferroni’s post hoc test. Fisher’s exact
test was used to determine significant differences in
LDA. Survival proportions were assessed by using a
Kaplan-Meier method and further analyzed with either
Wilcoxon or log-rank test. Proliferation, MSFE,
migration index, and Ki67 staining are normalized to the
vehicle group (100%). A P value of less than 0.05 was
considered significant.
Results
Enhanced iNOS expression correlates with poor patient
survival in invasive TNBC
iNOS has been described to be mediator of metastasis in dif-
ferent cancer types [20,21]. Elevated iNOS expression has
been linked to poor survival in patients with ERα-negative
breast cancer [7]. We hypothesized that enhanced iNOS
expression in TNBC correlates with poor patient survival
and metastases. Oncomine Cancer Microarray database ana-
lysis of NOS2 expression in TCGA breast database showed
higher NOS2 expression in invasive TNBC (n = 46) versus
non-TNBC (n= 250) (fold change 1.425, P= 3.85 × 10−5)
(Figure 1A). Patient survival analysis demonstrated a correl-
ation between increased NOS2 expression and worse
survival at 5 years in patients with invasive ductal breast
carcinoma (n = 79) (fold change 1.275, P= 0.037) (Figure 1B).
We further examined whether NOS2 expression correlates
with worse survival in two additional databases of
TNBC. Analysis of Van de Vijver (n = 69 samples) [17]
and Curtis (n = 260 samples) [18] databases confirmed
that high NOS2 expression was associated with poor survival
in patients with TNBC (Figure 1C and D).
Next, we examined iNOS protein expression by immu-
nohistochemistry in 83 surgically resected TNBC pri-
mary breast cancer samples, and correlated expression
with known patient outcome. iNOS was primarily cyto-
plasmic, but some cells exhibited both cytoplasmic and
nuclear localization (Figure 1E). Overall score showed
that iNOS levels were weak to moderate (score 3 or 4)
in 14 samples (16.9%) (Figure 1E, score 3 or 4), moderate
to strong (score 5 or 6) in 50 samples (60.2%) (Figure 1E),
and strong (score 7) in 19 specimens (22.9%) (Figure 1E).
This stratification was used to analyze the correlation
of iNOS expression and patient survival by using the
Kaplan-Meier analysis. We confirmed that enhanced
iNOS protein levels were associated with worse patient sur-
vival when compared with low iNOS expression (P= 0.05)
(Figure 1F). These results demonstrate that increased iNOS
by mRNA and protein expression in invasive TNBC is asso-
ciated with poor patient survival.
Inhibition of iNOS decreases cell proliferation, migration,
and mammosphere formation of TNBC cells
High concentrations of 1400 W (1, 2, and 4 mM) signifi-
cantly decreased proliferation in both cell lines (Figure 2A).
Similar results were observed for L-NAME (Additional
file 1: Figure S1A). L-NMMA at the highest concentra-
tion (4 mM) showed anti-proliferative activity in both
cell lines (Figure 2B). Resistance to treatment and me-
tastasis may arise from a subpopulation of CSCs within
a heterogeneous primary cancer [22,23]. iNOS inhibition
decreased primary MSs in both cell lines (Figure 2C;
Additional file 1: Figure S1B; Additional file 2: Figure S2A;
and Additional file 3: Figure S3A). We found reduced sec-
ondary MS in both cell lines for all the inhibitors tested
(Figure 2D; Additional file 1: Figure S1C; Additional file 2:
Figures S2B; and Additional file 3: Figure S3B). We show
enhanced iNOS expression in invasive TNBC (Figure 1A);
we then investigated the role of iNOS in cell migration.
Selective iNOS inhibition with 1400 W caused a marked
dose-dependent decrease in migration in both cell lines
(Figure 2E and Additional file 1: Figure S1D). L-NMMA-
treated cells showed reduction in migration capacity
(Figure 2F and Additional file 1: Figure S1E). Similar results
were found for L-NAME (Additional file 4: Figure S4A).
These results were further confirmed in siRNA-mediated
iNOS (NOS2) knockdown MDA-MB-231 (Figure 3A-C)
and SUM159 cells (Additional file 5: Figure S5A, B,
and C). Collectively, the results indicate that basal levels
of iNOS have a major role in CSC self-renewal and
migrating properties of TNBC cell lines and a less
pronounced effect on proliferation.
Suppression of endogenous iNOS could impair EMT and
cell migration by impairing HIF1α and the endoplasmic
reticulum stress/TGFβ/AFT4/ATF3 crosstalk
EMT is evoked during tumor invasion and metastasis
[3,24]. We examined the impact on NOS isoforms (iNOS,
eNOS, and nNOS) after either selective or pan-inhibition
(Figure 3D and Additional file 4: Figure S4B, C, and F).
Selective iNOS blockade with 1400 W caused a reduc-
tion in protein levels of the EMT transcription factors
Snail, Slug, and Twist1 (Figure 3D and Additional file 4:
Figure S4D). Zeb1 protein levels were decreased at milli-
molar concentrations (Figure 3D). Though less consistent,
similar results were found for the pan-NOS inhibitors
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(Additional file 4: Figure S4E and F). iNOS knockdown
with siRNA correlated with a decrease of Zeb1 and Twist1
protein levels in both cell lines (Figure 3E). Overall, these
data suggest that selective iNOS inhibition efficiently de-
creases migration of TNBC cell lines, and this is consist-
ently correlated with a decrease of EMT transcription
factors.
Different pathways are responsible for inducing EMT
and metastasis of tumor cells; among them, NO is a com-
mon denominator of HIF1α and endoplasmic reticulum
(ER) stress [25-27]. Our findings indicate that selective
iNOS inhibition resulted in a dose-dependent decrease
in hypoxia (HIF1α) (Figure 3F and Additional file 4:
Figure S4G) and the ER stress markers IRE1α/splicedXBP1
(Figure 3F and Additional file 5: Figure S5E) and ATF4
(activating transcription factor 4) in both cell lines
(splicedXBP1 was not detected in SUM159 cells; data not
shown) (Figure 3F). Functional protein-protein interaction
analysis unveiled a link between iNOS and TGFβ1
(Additional file 5: Figure S5D). We confirmed that
1400 W is able to inhibit transforming growth factor
β (TGFβ) signaling in the absence (Figure 3G) and
presence of recombinant TGFβ1 (Additional file 5:
Figure S5F) through an undetermined mechanism.
Additional protein-protein interaction analyses showed an
interaction between ATF4 and ATF3 (activating transcrip-
tion factor 3) (Additional file 5: Figure S5D), both activat-
ing transcription factors that interact with TGFβ [28,29].
We confirmed the crosstalk between ER stress through
ATF4/ATF3 and TGFβ (Additional file 5: Figure S5G);
similarly, recombinant TGFβ1 induced the PERK/eIF2α/
ATF4/ATF3 axis (Figure 3H). Our results show that
co-treatment of the iNOS inhibitor 1400 W and recom-
binant TGFβ1 (pretreatment for 7 days) for 24 hours was
able to inhibit the stimulation of ATF4 and ATF3 protein
levels by TGFβ1 independently of the PERK/eIF2α
pathway. This result was further confirmed in siRNA-
mediated iNOS knockdown cells (Figure 3I). Overall,
our data demonstrate that iNOS inhibition could impair
EMT and tumor cell migration by impairing ER stress
(IRE1α/XBP1) and the crosstalk between ATF4, ATF3,
and TGFβ.
iNOS inhibition reduces tumor growth and tumor-initiating
capacity and prevents lung metastases in mouse models
of TNBC
Considering our in vitro data, we next investigated whether
L-NAME was able to prevent tumor initiation and metas-
tasis of MDA-MB-231 L/G cells in mice. L-NAME signifi-
cantly reduced tumor growth (P = 0.001) (Figure 4A) as
well as primary MS (Figure 4B). Additionally, tumor-
initiating capacity of CSCs was assessed with LDA. All of
the animals of the vehicle group developed tumors, but
treatment with L-NAME yielded 3/5 tumors at 1.5 weeks
with 5 × 105 cells. The same results were observed in the
vehicle group at 2.5 weeks with 1 × 105 cells compared
with the L-NAME-treated group (0/5 tumors) (P <0.05)
(Figure 4D). Ex vivo imaging of lungs in the presence of
luciferin showed higher fluorescence in the vehicle
group compared with the L-NAME group (Figure 4C).
These results suggest that iNOS inhibition with daily
L-NAME may prevent metastasis to lungs in a TNBC
mouse model.
To translate our results into future clinical trials, we
used the pan-NOS inhibitor L-NMMA for further study.
This is the first report using this drug re-purposed for
this indication, with a paucity of data on the effective
preclinical dose as an anti-cancer therapeutic. Thus,
daily injections of 80 mg/kg L-NMMA were first given
to SUM159 xenograft-bearing mice alone or in combin-
ation with docetaxel. After 10 days, no differential effect
was observed between groups, and the daily dose was in-
creased to 200 mg/kg. The tumor growth was efficiently
blocked by L-NMMA administered alone or in combin-
ation with docetaxel (Additional file 6: Figure S6A).
Higher proliferating rate (Ki67) in the vehicle and chemo-
therapy groups compared with the L-NMMA and com-
bination groups (Additional file 6: Figure S6B and C) was
observed. L-NMMA efficiently blocked the docetaxel-
enhanced MSFE (Additional file 6: Figure S6D). LDA
showed that the docetaxel and combination groups exhib-
ited 12/12 and 6/12 tumors, respectively, at 7 weeks with
5 × 104 cells. At week 9, we observed significant reduction
in tumor-initiating capacity as different groups with
2 × 104 cells yielded 3/12 and 0/12 tumors in docetaxel
(See figure on previous page.)
Figure 1 Enhanced nitric oxide synthase 2 (NOS2) expression correlates with poor patient survival in invasive triple-negative breast
cancer (TNBC). (A) Higher NOS2 mRNA expression in invasive TNBC versus non-TNBC (P = 3.85 × 10−5). (B) High NOS2 expression correlates with
death at 5 years in invasive breast carcinoma (P = 0.037). Kaplan-Meier survival analyses in (C) Van de Vijver (n = 69; P = 0.04) and (D) Curtis (n = 260;
P = 0.01) breast databases show that high NOS2 expression correlates with worse overall survival of patients with TNBC. (E) Immunohistochemical
analysis of TNBC human samples for inducible nitric oxide synthase (iNOS) protein expression. Weak-to-moderate (3 or 4), moderate-to-strong (5 or 6),
and strong (7) were the cutoffs established for further analysis of survival. Several samples showed expression in both tumor (T) and stromal (S) cells (original
optical objective: 20×). MDA-MB-231 cells transfected with either NOS2-directed shRNA (shRNA1) or empty vector (EV) were used as negative and positive
control of iNOS staining, respectively (original optical objective: 10×). Counterstain: hematoxylin. (F) Increased iNOS expression is associated with less patient
survival when compared with low iNOS expression. Kaplan-Meier survival analysis of TNBC human patient samples (n = 83) (P= 0.05). shRNA1, small hairpin
RNA 1; TCGA, The Cancer Genome Atlas.
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Figure 2 Effects of inducible nitric oxide synthase (iNOS) inhibitors on tumor cell proliferation, migration, and mammosphere
formation in triple-negative breast cancer (TNBC) cell lines. Proliferation (A, B) and primary (C) and (D) secondary mammosphere,
and migration index of MDA-MB-231 and SUM159 cell lines treated with 1400 W (E) and L-NMMA (F) for 96 hours. Results were
normalized to vehicle. Data are presented as mean ± standard error of the mean. *P <0.05, **P <0.01, ***P <0.001, ****P <0.0001. 1400 W,
N-[[3-(aminomethyl)phenyl]methyl]-ethanimidamide; L-NMMA, NG-monomethyl-L-arginine; MSFE, mammosphere-forming efficiency.
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and combination, respectively (P <0.05) (Additional
file 6: Figure S6E).
Similarly, docetaxel and L-NMMA (200 mg/kg, daily)
were given to MDA-MB-231 xenograft-bearing mice.
We found reduced tumor growth in the L-NMMA group
compared with vehicle, but there was no change between
the docetaxel and combination groups (Figure 5A). These
results were further correlated with lower proliferation
rate (Ki67) in the L-NMMA and combination groups
(Figure 5B and C). Additionally, higher apoptosis levels
in docetaxel-treated xenografts were found; these results
might offset the high proliferation rate relative to the com-
bination group (Figure 5D). A decrease in MS formation
was seen for both L-NMMA and combination compared
with vehicle and chemotherapy alone (Figure 5E). LDA
showed that the vehicle-treated and docetaxel-treated
groups presented 12/12 and 8/12 tumors, respectively,
with a significant decrease in L-NMMA-treated (1/12)
and combination-treated (4/12) xenografts at 5 weeks
with 5 × 104 cells. After 6 weeks, a decrease in both the
L-NMMA and combination groups (3/12 and 5/12, respect-
ively) compared with the vehicle and docetaxel groups (6/12
and 8/12, respectively) was observed (P <0.05) (Figure 5F).
Our results in the MDA-MB-231 xenograft model do not
show additional benefit over chemotherapy in terms of
tumor volume; however, it is clear that the benefits of
L-NMMA lie in the ability of this inhibitor to reduce
self-renewal and tumor initiation capacities of CSCs.
Our investigations demonstrate that L-NMMA plasma
levels are cleared rapidly (Additional file 7: Figure S7A),
whereas it accumulates in the tumor tissue (Additional file 7:
Figure S7B) and inhibits the conversion of L-arginine to
L-citrulline and NO by iNOS (Additional file 7: Figure S7C)
24 hours after completion of treatment. This inhibition led
to a decrease in total NO production as seen in SUM159
cells (Additional file 7: Figure S7D). Overall, these results
demonstrate that in vivo iNOS inhibition with L-NMMA
decreased tumor growth, cell proliferation, and tumor-
initiating capacity of CSCs, together with a significant reduc-
tion in lung metastases.
Efficient dose regimen of L-NMMA and docetaxel with
potential clinical application
Clinically, L-NMMA causes acute BP elevation through
inhibition of constitutive eNOS [30]. Here, we propose a
regimen with an attenuated duration of L-NMMA, at a
dose comparable to that previously described clinically
[31], together with the anti-hypertensive amlodipine and
docetaxel. Oral L-NMMA significantly increased the mean
systolic pressure compared with basal levels in mice, and
this elevation was efficiently reversed by amlodipine
(Figure 6A). This elevation in BP was transient and dis-
appeared 24 hours after the last injection of L-NMMA
(Figure 6B).
The combination of L-NMMA, amlodipine, and doce-
taxel was able to decrease tumor growth in an MDA-MB-
231 orthotopic model (Figure 6C). This dose regimen also
improved survival in comparison with the docetaxel-
treated group (P = 0.0001) (Figure 6D). Similar results
were found in SUM159 xenografts (Figure 6E). We
tested the effect of amlodipine on tumor volume in
MDA-MB-231 tumor-bearing mice (n = 5 per group).
A significant reduction in tumor volume was observed
in docetaxel + amlodipine + L-NMMA compared with
docetaxel (P <0.001), docetaxel + amlodipine (P <0.01),
and docetaxel + L-NMMA (P <0.05) (Figure 6F). Overall,
these data show that the dose regimen proposed herein is
effective in reducing tumor growth and may result in im-
proved survival.
Discussion
TNBC is an extremely aggressive and lethal form of can-
cer lacking effective targeted therapies. Patients with
TNBC show higher risk of metastasis and tumor relapse
[1,2]. We have recently described two novel cancer genes
(RPL39 and MLF2) that are important for tumor initi-
ation and metastasis and are regulated by the NO signal-
ing pathway [32]. iNOS predicts for worse survival in
patients with basal-like ER-negative breast cancer and
has been suggested to increase tumor aggressiveness by
modulating CSCs as well as the metastatic propensity of
(See figure on previous page.)
Figure 3 iNOS knockdown impairs tumorigenicity and EMT by a dual impact on HIF1α and ER stress/TGFβ/AFT4/ATF3 crosstalk.
Proliferation (A), migration (B), and mammosphere-forming efficiency (MSFE) (C) in MDA-MB-231 cells transiently transfected with two different
NOS2-directed siRNAs (siRNA1 and siRNA2) compared with scrambled control. Western blot analysis of NOS isoforms (iNOS, eNOS, and nNOS) and
EMT transcription factors in MDA-MB-231 and SUM159 cell lines treated with (D) 1400 W and (E) siRNA-mediated NOS2 knockdown. (F) Selective
iNOS inhibition reduced hypoxia (HIF1α) and ER stress markers (IRE1α and ATF4). (G) Phospho-Smad2/3, Smad2/3, and mature TGFβ protein levels
in MDA-MB-231 and SUM159 cells. (H) Recombinant TGFβ1 (10 ng/mL for 7 days) activates the PERK/eIF2α/ATF4/ATF3 axis in MCF10A. (I) Effects
on the PERK/eIF2α/ATF4/ATF3 axis by co-treatment of recombinant TGFβ1 (10 ng/mL, 7 days) and 1400 W (4 mM) for 24 hours in MCF10A cells.
iNOS, ATF4, ATF3, and mature TGFβ protein levels in siRNA-mediated NOS2 knockdown (siRNA2) MCF10A cells for 96 hours. (J) Selective iNOS
inhibition is postulated to impair EMT and tumor cell migration by an impact on HIF1α, ER stress (IRE1α/XBP1), and the crosstalk between
ATF4, ATF3, and TGFβ. Results were normalized to scrambled. Data are presented as mean ± standard error of the mean. ****P <0.0001.
1400 W, N-[[3-(aminomethyl)phenyl]methyl]-ethanimidamide; ATF3, activating transcription factor 3; ATF4, activating transcription factor 4;
EMT, epithelial-mesenchymal transition; ER, endoplasmic reticulum; HIF1α, hypoxia-inducible factor 1α; iNOS, inducible nitric oxide synthase;
siRNA, small interfering RNA; TGFβ, transforming growth factor β.
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Figure 4 Decrease in tumor initiation and lung metastases in MDA-MB-231 xenografts. (A) Tumor volume of MDA-MB-231 breast xenografts
(n = 5 per group) after daily injection of L-NAME (80 mg/kg, intraperitoneal). (B) Primary and secondary mammosphere of cancer cells isolated from
tumor tissue. (C) Luminescence of MDA-MB-231 L/G tumor cells in lungs of vehicle- and L-NAME-treated mice. (D) Tumor-initiating
capacity of tumor cells (limiting dilution assay). Results were normalized to vehicle. Data are presented as mean ± standard error of the
mean. *P <0.05, **P <0.01, ***P <0.001. L-NAME, N5-[imino(nitroamino)methyl]-L-ornithine methyl ester; MSFE, mammosphere-forming efficiency.
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cells [7]. This is the first report demonstrating that iNOS
inhibition decreases tumorigenicity of TNBC cells by
affecting cell proliferation, CSC self-renewal, and migra-
tion. Our in vivo experiments demonstrate the efficacy
of a small-molecule iNOS inhibitor L-NMMA as a
potential novel targeted therapy in patients with TNBC
with immediate translation into human clinical trials.
We report that NOS2 is commonly increased in invasive
TNBC and is associated with poor survival of patients
with invasive breast carcinoma. We provide additional
data that high iNOS protein levels by immunohistochem-
istry in samples of patients with TNBC also correlate
with worse outcome, consistent with earlier reports in
ERα-negative [8] and invasive breast carcinoma [33].
Kaplan-Meier analysis of the Van de Vijver and Curtis
databases as well as of the human TNBC patient sam-
ples strongly indicate that high iNOS expression is as-
sociated with poor overall survival in patients with
TNBC. These observations establish that increased iNOS
expression may be a marker of poor prognosis in patients
with breast cancer [6-9].
iNOS expression has been correlated with increased
tumor grade and aggressiveness of breast cancer cells
[7,9]. Here, we describe the effect of iNOS on CSC self-
renewal, tumor initiation, and the migrating capacity of
TNBC cells. The anti-tumor activity of iNOS inhibitors
has been previously reported in oral [34], glioblastoma
[13], and breast cancer [35-38] and is consistent with our
findings. Increased iNOS expression has been described to
contribute to resistance to conventional treatment by
promoting tumor initiation in glioblastoma cells [13,38].
Additionally, iNOS may influence CSC self-renewal by
modulating CD44 and c-Myc in ERα-negative breast can-
cer [7]. We demonstrate for the first time that iNOS in-
hibition decreased CSC self-renewal and tumor initiation
in TNBC.
NO may either promote or inhibit metastatic events
depending on endogenous levels [5]. The role of NOS
inhibitors on metastasis has been previously studied, but
the underlying mechanisms remain unclear. An early
study demonstrated that the pan-NOS inhibitor L-NAME
may decrease tumor growth and lung metastasis in a
murine breast cancer model (EMT-6 cells) [39]. Similarly,
L-NAME inhibited the invasive and migrating potential of
two metastatic mammary cell lines (C3L5 and C10) [40].
In a study with the metastatic human adenocarcinoma
HRT-18 cells, the invasiveness was substantially decreased
by daily treatment with 500 μM of the selective iNOS in-
hibitor 1400 W [41]. More recently, 1400 W was shown
to markedly inhibit spontaneous lung metastasis in a
mouse model of adenoid cystic carcinoma of the oral cav-
ity [34]. Our present results demonstrate that iNOS inhib-
ition decreases cell migration and lung metastases in
TNBC. It has been suggested that NO and iNOS may lead
to early metastasis by inducing IL-8 [7] and the CXC
chemokine receptor 4 [42]. CSCs display mesenchymal
features [2], resulting in increased cell migration and
metastasis. iNOS inhibition decreased CSC self-renewal
and tumor initiation, thus indicating that inhibitors
against this pathway could reverse the transition of
tumor cells to a more mesenchymal-like phenotype.
Consistent with the effect on cell migration, selective iNOS
inhibition and NOS2 knockdown decreased transcription
factors driving EMT in all of the TNBC cell lines tested.
EMT may be promoted by different signal transduc-
tion pathways like TGFβ, Wnt/β-catenin, Notch, and
Hedgehog and multiple growth factors. EMT transcrip-
tion factors (Snail, Slug, Twist1, or Zeb1) are activated
by diverse intermediate effectors like c-Myc, Ets, HIF1α,
or NFκB [43]. Additionally, ER stress has been linked to
EMT in thyroid, alveolar epithelial, and human renal
proximal tubule cells through activation of PERK, XBP1,
or Grp78 [27,44-46]. Interestingly, among these dispar-
ate signaling networks, iNOS is the common denomin-
ator between HIF1α and ER stress [25-27]. Inhibition of
endogenous iNOS-derived NO production was able to
reduce HIF1α stabilization and protein levels in colon
carcinoma cells [47]. Transcription factors Twist1, Snail,
Slug, and Zeb1, among others, are directly or indirectly
influenced by HIF1α [26]. Additionally, hypoxia induces
ER stress and unfolded protein response and was recently
linked to migration and sphere formation in breast cancer
cells by activation of the PERK/ATF4/LAMP3 arm under
hypoxic conditions [48]. Our results suggest that iNOS
inhibition correlates with an impairment of TGFβ sig-
naling via the ER stress ATF4/ATF3 axis. It is known
that TGFβ stimulates ATF4 protein levels to suppress
differentiation in calvarial osteoblasts [29]. Certain
conditions such as ER stress through the PERK/eIF2α
axis may activate ATF4, which in turn induces ATF3
(See figure on previous page.)
Figure 5 In vivo effects of L-NMMA in MDA-MB-231 xenografts. (A) Tumor volume of MDA-MB-231 breast xenografts (n = 10 per group)
treated with vehicle, L-NMMA, docetaxel, and combination. (B) Illustrative images of Ki67 staining in the vehicle, L-NMMA, docetaxel, and
combination groups. Original optical objective: 10×. Counterstain: hematoxylin. (C) Cell proliferation of tumor xenografts with Ki67 immunostaining.
(D) Nuclear cleaved caspase-3 staining in the chemo and combo groups. (E) Primary and secondary mammosphere of breast cancer cells
isolated from tumor tissue. (F) Tumor-initiating capacity of tumor cells. Results were normalized to vehicle. For proliferation and apoptosis,
1,000 cells were counted from 10 different fields, and the percentage was determined. Data are presented as mean ± standard error of the
mean. *P <0.05, **P <0.01, ***P <0.001, ****P <0.0001. L-NMMA, NG-monomethyl-L-arginine; MSFE, mammosphere-forming efficiency.
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Figure 6 Clinically relevant dose regimen of L-NMMA in orthotopic mouse models of triple-negative breast cancer. (A) Mean systolic
pressure of mice (n = 5) giving one cycle of the dose rate proposed in this study. (B) Mean systolic pressure of mice 30 minutes and 24 hours
after the last injection of one cycle treatment (n = 5). (C) Tumor volume of MDA-MB-231 xenografts (n = 10 per group) treated with vehicle, docetaxel,
and combination (docetaxel + amlodipine + L-NMMA). (D) Kaplan-Meier survival curve of vehicle-, chemotherapy-, and combo-treated MDA-MB-231
xenograft-bearing mice. (E) Tumor volume of SUM159 xenografts (n = 10 per group) treated with vehicle, docetaxel, and combination.
(F) Effects of amlodipine on tumor volume in MDA-MB-231 xenografts (n = 5 per group). Data are presented as mean ± standard error of the
mean. *P <0.05, **P <0.01, ***P <0.001, ****P <0.0001. L-NMMA, NG-monomethyl-L-arginine; ns, not significant.
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transcription [49], whereas ATF3 itself is an activating
transcription factor that enhances TGFβ, MS forma-
tion, and EMT in cooperation with Twist1 [28].
To determine a safe and effective regimen with clinical
applicability was the main challenge of these preclinical
studies. L-NMMA is a pan-NOS inhibitor that has been
extensively studied in several clinical trials of circulatory
shock [30]. In the cardiogenic shock trial, L-NMMA was
safe and had few adverse events other than transient
reversible hypertension [31]. In normotensive patients,
L-NMMA was administered to patients with meta-
static renal cell carcinoma prior to infusion of IL-2
[31]. Doses of 3 and 6 mg/kg did not induce clinically
apparent side effects, and BP remained unchanged. At
a dose level of 12 mg/kg, patients experienced an in-
crease in systolic BP up to 25 mm Hg, without any
clinical symptoms, which normalized rapidly on stop-
ping the L-NMMA infusion. The dose rate in the
present study was chosen, with modifications, on the
basis of a previous clinical trial in patients with septic
shock [31]. Our results demonstrate that tumor growth
can be restrained by an attenuated regimen of 5 days
of L-NMMA after chemotherapy, given together with
amlodipine. López et al. [50] carried out a randomized,
placebo-controlled, double-blind study of L-NMMA in
patients with septic shock up to a maximum of 14 days.
The regimen followed consisted of an initial dose of
2.5 mg/kg per hour and then was adjusted at different
rates (0.5, 1, 2.5, 5, 7.5, 10, 15, and 20 mg/kg per hour).
The current proposed dose regimen to be clinically
tested as a novel anti-cancer therapeutic is at much
lower total doses, which have been described [50].
Conclusions
Our study provides new knowledge about the correlation
between enhanced endogenous iNOS expression and
poor survival in patients with TNBC. We show that the
targeted therapy with iNOS inhibitors is able to inhibit
not only tumor cell proliferation but also CSC self-
renewal and migration, reducing tumor growth, tumor
initiation, and the number of lung metastases. We sug-
gest that inhibition of metastatic events may be due to a
reduction of EMT transcription factors by inhibition of
HIF1α, ER stress (IRE1α/splicedXBP1), and the TGFβ/
ATF4/ATF3 axis. Finally, we propose a targeted thera-
peutic regimen, which decreases tumor growth and en-
hances survival rate in vivo; clinical trials targeting this
pathway in patients with TNBC are being planned.
Additional files
Additional file 1: L-NAME, 1400 W, and L-NMMA (micromolar range)
on proliferation, migration, and mammosphere formation of TNBC cell
lines. Proliferation (A) and primary (B) and secondary (C) mammospheres
of MDA-MB-231 and SUM159 cell lines treated with L-NAME. Impact of
1400 W (D) and L-NMMA (E) at micromolar concentrations on the migration
index in MDA-MB-231 and SUM159 cells. Results were normalized to
vehicle. Data are presented as mean ± standard error of the mean.
*P <0.05, **P <0.01, ***P <0.001, ****P <0.0001. 1400 W, N-[[3-(aminomethyl)
phenyl]methyl]-ethanimidamide; L-NMMA, NG-monomethyl-L-arginine;
TNBC, triple-negative breast cancer.
Additional file 2: Representative images of mammospheres in
MDA-MB-231 cells treated with iNOS inhibitors. Illustrative images of
primary (A) and secondary (B) mammospheres after treatment with
1400 W, L-NMMA (vehicle, 1, 2, 4 mM), and L-NAME (vehicle, 1, 2, 5 mM)
for 96 hours. 1400 W, N-[[3-(aminomethyl)phenyl]methyl]-ethanimidamide;
L-NAME, N5-[imino(nitroamino)methyl]-L-ornithine methyl ester; L-NMMA,
NG-monomethyl-L-arginine; iNOS, inducible nitric oxide synthase.
Additional file 3: Representative images of mammospheres in
SUM159 cells treated with iNOS inhibitors. Illustrative images of
primary (A) and secondary (B) mammospheres after treatment with
1400 W, L-NMMA (vehicle, 1, 2, 4 mM), and L-NAME (vehicle, 1, 2, 5 mM)
for 96 hours. 1400 W, N-[[3-(aminomethyl)phenyl]methyl]-ethanimidamide;
L-NAME, N5-[imino(nitroamino)methyl]-L-ornithine methyl ester; L-NMMA,
NG-monomethyl-L-arginine; iNOS, inducible nitric oxide synthase.
Additional file 4: Migration and Western blot of NOS isoforms, EMT
transcription factors, and hypoxia in TNBC cell lines treated with
iNOS inhibitors. (A) Tumor cell migration after treatment with L-NAME
in MDA-MB-231 and SUM159 cell lines. (B, C) Western blot analysis of
NOS isoforms (iNOS, eNOS, and nNOS) in MDA-MB-231 and SUM159 cells
treated with 1400 W and L-NMMA. (D, E) EMT markers protein levels in
MDA-MB-231 and SUM159 cells after treatment with micromolar concentrations
of 1400 W or L-NMMA. (F)Western blot analysis of NOS isoforms and the
EMT transcription factors in MDA-MB-231 and SUM159 cell lines
treated with L-NAME. (G) Quantification of HIF1α protein levels relative
to β-actin in MDA-MB-231 and SUM159 cells treated with 1400 W. Results
were normalized to vehicle. Data are presented as mean ± standard error of
the mean. *P <0.05, **P <0.01. 1400 W, N-[[3-(aminomethyl)phenyl]methyl]-
ethanimidamide; EMT, epithelial-mesenchymal transition; eNOS, endothelial
nitric oxide synthase; HIF1α, hypoxia-inducible factor 1α; iNOS, inducible
nitric oxide synthase; L-NAME, N5-[imino(nitroamino)methyl]-L-ornithine
methyl ester; L-NMMA, NG-monomethyl-L-arginine; iNOS, inducible nitric
oxide synthase; nNOS, neuronal nitric oxide synthase; TNBC, triple-negative
breast cancer.
Additional file 5: NOS2 knockdown decreases cell proliferation,
migration, mammosphere formation, spliced XBP1, and Smad2/3
signaling. Crosstalk between ER stress and TGFβ is shown. Proliferation
(A), migration (B), and mammospheres (C) of SUM159 cells transiently
transfected with two different NOS2-directed siRNAs (siRNA1 and siRNA2)
compared with scrambled control. (D) Protein-protein interaction analysis
(STRING 9.1) deciphered a link between NOS2, TGFβ1, and ATF4/ATF3
axis. (E) Unspliced XBP1 (uXBP1), spliced XBP1 (sXBP1), and β-actin RT-PCR
cDNA amplicons from MDA-MB-231 cells treated with 1400 W for 96 hours.
(F) The iNOS inhibitor 1400 W is able to reduce the Smad2/3 signaling in
MDA-MB-231 cells under treatment with recombinant TGFβ1 (10 ng/mL) for
72 hours. (G) Tunicamycin (5 μM) confirmed the crosstalk between ER stress
and TGFβ through ATF4/ATF3 transcription factors. Results were normalized
to scrambled control. Data are presented as mean ± standard error of
the mean. *P <0.05, **P <0.01, ***P <0.001, ****P <0.0001. 1400 W,
N-[[3-(aminomethyl)phenyl]methyl]-ethanimidamide; ATF3, activating
transcription factor 3; ATF4, activating transcription factor 4; ER, endoplasmic
reticulum; iNOS, inducible nitric oxide synthase; NOS2, nitric oxide synthase
2; RT-PCR, reverse transcription-polymerase chain reaction; shRNA, small
hairpin RNA; siRNA, small interfering RNA; TGFβ, transforming growth
factor β.
Additional file 6: In vivo effects of L-NMMA in SUM159 xenografts.
(A) Tumor volume of SUM159 breast xenografts (n = 10 per group)
treated with vehicle, L-NMMA, chemotherapy, and combination. (B) Illustrative
images of Ki67 staining in vehicle, L-NMMA, chemotherapy (docetaxel), and
combination groups. Original optical objective: 10×. Counterstain: hematoxylin.
(C) Cell proliferation of tumor xenografts is depicted as Ki67-positive cells. Cells
(1,000) were counted from 10 different fields, and the percentage was
determined. (D) Primary and secondary mammospheres of breast
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cancer cells isolated from tumor tissue. (E) Tumor-initiating capacity of
tumor cells assayed by the limiting dilution method. Results were
normalized to vehicle. Data are presented as mean ± standard error of
the mean. *P <0.05, **P <0.01, ***P <0.001, ****P <0.0001. L-NMMA,
NG-monomethyl-L-arginine.
Additional file 7: L-NMMA levels in plasma and tumor tissue.
(A, B) Ratiometric quantification of methylarginine in plasma and
tumor tissue (MDA-MB-231 and SUM159 xenografts) by liquid
chromatography-tandem mass spectrometry (LC-MS/MS). (C) iNOS catalyzes
the reaction of L-arginine to L-citrulline + nitric oxide (NO). Ratiometric
quantification of citrulline in SUM159 xenograft tissue by LC-MS/MS.
(D) Total NO production in SUM159 cells treated with L-NMMA and
1400 W (4 mM) for 0.5, 2, 6, and 24 hours. Results were normalized to
vehicle. Data are presented as mean ± standard error of the mean. *P <0.05,
**P <0.01, ***P <0.001, ****P <0.0001. 1400 W, N-[[3-(aminomethyl)phenyl]
methyl]-ethanimidamide; L-NMMA, NG-monomethyl-L-arginine; iNOS,
inducible nitric oxide synthase.
Abbreviations
1400 W: N-[[3-(aminomethyl)phenyl]methyl]-ethanimidamide;
ANOVA: analysis of variance; ATF3: activating transcription factor 3;
ATF4: activating transcription factor 4; BP: blood pressure; CSC: cancer stem
cell; DMEM: Dulbecco’s modified Eagle’s medium; EMT: epithelial-mesenchymal
transition; eNOS: endothelial nitric oxide synthase; ER: endoplasmic reticulum;
ERα: estrogen receptor alpha; HIF1α: hypoxia-inducible factor 1α; IL-8: interleukin-8;
iNOS: inducible nitric oxide synthase; i.p.: intraperitoneal; LDA: limiting
dilution assay; L-NAME: N5-[imino(nitroamino)methyl]-L-ornithine methyl
ester; L-NMMA: NG-monomethyl-L-arginine; MS: mammosphere;
MSFE: mammosphere-forming efficiency; nNOS: neuronal nitric oxide
synthase; NO: nitric oxide; NOS: nitric oxide synthase; PCR: polymerase
chain reaction; SCID: severe combined immunodeficiency; shRNA: small
hairpin RNA; siRNA: small interfering RNA; TCGA: The Cancer Genome
Atlas; TGFβ: transforming growth factor β; TNBC: triple-negative breast
cancer.
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